Agios moves international headquarters to the Greater Zurich Area

The American biopharmaceutical company Agios has relocated its international headquarters from the USA to the Greater Zurich Area. Reasons behind the move include the wealth of life science innovation and the talented workforce in the region.

Generic Image: Unsplash


Agios has moved its international headquarters to Zug, announced the canton of Zug in a statement. Company representatives were impressed by life science innovation in the region, according to the statement. The talented workforce also persuaded the move. 

Orlando Oliveira, Vice President of Agios, highlighted other key factors behind the decision: the centrality in Europe, great infrastructure, outstanding quality of life and great support from the local authorities.

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases. A leader in the field of cellular metabolism, the company was founded in 2008 in Cambridge in the US state of Massachusetts. It is listed on the American Nasdaq stock exchange. 

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program